Collision
发表于 2025-3-26 23:40:26
http://reply.papertrans.cn/23/2283/228259/228259_31.png
我还要背着他
发表于 2025-3-27 03:26:08
http://reply.papertrans.cn/23/2283/228259/228259_32.png
Recessive
发表于 2025-3-27 07:33:23
Clinical Trials for Erectile Dysfunction in Parkinson’s Diseaseents of ED in PD remain scarce, and existing studies were limited by small sample size and open-label methodology. Therefore, well-designed double-blind RCTs are required to further understand the efficacy and adverse effect profiles of these treatments in PD.
暂时休息
发表于 2025-3-27 13:26:11
http://reply.papertrans.cn/23/2283/228259/228259_34.png
invade
发表于 2025-3-27 16:34:14
http://reply.papertrans.cn/23/2283/228259/228259_35.png
commune
发表于 2025-3-27 19:08:13
http://reply.papertrans.cn/23/2283/228259/228259_36.png
野蛮
发表于 2025-3-27 22:46:00
B. D. Tapley,A. R. Neto,B. E. Schutzutic approaches. This chapter will discuss the terminology and definition of depression, anxiety, apathy, and fatigue in PD, their differentiation from other PD- and non–PD-related symptoms, subtyping, physiological markers, as well as considerations related to the optimal outcome measures and design of clinical trials.
GLADE
发表于 2025-3-28 03:14:37
https://doi.org/10.1007/978-981-10-3713-9tools to assess subjective and objective outcome measures, and the pitfalls and considerations pertaining each of these methods. Clinical trials will be reviewed to identify strengths and weaknesses, and lastly, a series of recommendations will be outlined for the design of clinical trials for constipation in Parkinson’s disease.
强制令
发表于 2025-3-28 07:23:24
Assessment of Nonmotor Symptoms in Rodent Models of Parkinson’s Diseaseimal models, although with some limitation..This chapter will provide an overview of the PD nonmotor symptoms in the most common toxin-based rodent models, highlighting their translational value for clinical investigations.
expunge
发表于 2025-3-28 10:51:19
http://reply.papertrans.cn/23/2283/228259/228259_40.png